Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kaye

Showing results (1131-1140 of 1,165) with videos related to

Pageof 117
Sort By:
Diabetes|September 14, 2011
Advanced glycation end products are direct modulators of β-cell functionMelinda T Coughlan, Felicia Y T Yap, David C K Tong, et al.
Circulation. Heart Failure|November 18, 2016
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection FractionDavid M Kaye, Gerd Hasenfuß, Petr Neuzil, et al.
Journal of the American College of Cardiology|September 1, 2017
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI StudySandeep Prabhu, Andrew J Taylor, Ben T Costello, et al.
Circulation|February 26, 2020
Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular DiseaseDavid M Kaye, Waled A Shihata, Hamdi A Jama, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Annals of Neurology|August 3, 2013
Eteplirsen for the treatment of Duchenne muscular dystrophyJerry R Mendell, Louise R Rodino-Klapac, Zarife Sahenk, et al.
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
European Heart Journal|August 19, 2025
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trialLouise Segan, Peter M Kistler, Shane Nanayakkara, et al.
Ebiomedicine|July 30, 2025
The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohortsTu'uhevaha J Kaitu'u-Lino, Teresa M MacDonald, Emerson Keenan, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Pageof 117

Showing results (1131-1140 of 1,165) with videos related to

Sort By:
Pageof 117
Diabetes|September 14, 2011
Advanced glycation end products are direct modulators of β-cell functionMelinda T Coughlan, Felicia Y T Yap, David C K Tong, et al.
Circulation. Heart Failure|November 18, 2016
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection FractionDavid M Kaye, Gerd Hasenfuß, Petr Neuzil, et al.
Journal of the American College of Cardiology|September 1, 2017
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI StudySandeep Prabhu, Andrew J Taylor, Ben T Costello, et al.
Circulation|February 26, 2020
Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular DiseaseDavid M Kaye, Waled A Shihata, Hamdi A Jama, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Annals of Neurology|August 3, 2013
Eteplirsen for the treatment of Duchenne muscular dystrophyJerry R Mendell, Louise R Rodino-Klapac, Zarife Sahenk, et al.
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
European Heart Journal|August 19, 2025
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trialLouise Segan, Peter M Kistler, Shane Nanayakkara, et al.
Ebiomedicine|July 30, 2025
The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohortsTu'uhevaha J Kaitu'u-Lino, Teresa M MacDonald, Emerson Keenan, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Pageof 117